Study of Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone (CHOP) With Ofatumumab in Patients With Richter's Syndrome (CHOP-OR)
Single Arm NCRI Feasibility Study of CHOP in Combination With Ofatumumab in Induction and Maintenance for Patients With Newly Diagnosed Richter's Syndrome
Sponsor: Cancer Research UK
A PHASE2 clinical study on Richter's Syndrome, this trial is completed. The trial is conducted by Cancer Research UK and has accumulated 7 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
May 2018 — Jun 2018 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
▶ Show 2 earlier versions
-
Jun 2017 — May 2018 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jan 2017 — Jun 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Apr 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cancer Research UK
- GlaxoSmithKline
- NCRI CLL Subgroup
- Oxford University Hospitals NHS Trust
- University of Oxford
For direct contact, visit the study record on ClinicalTrials.gov .